Format

Send to

Choose Destination
Immunity. 2015 Jan 20;42(1):55-67. doi: 10.1016/j.immuni.2014.12.031.

A20 restricts ubiquitination of pro-interleukin-1β protein complexes and suppresses NLRP3 inflammasome activity.

Author information

1
Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
2
Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA 94143, USA.
3
Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA. Electronic address: averil.ma@ucsf.edu.

Abstract

Inappropriate inflammasome activation contributes to multiple human diseases, but the mechanisms by which inflammasomes are suppressed are poorly understood. The NF-κB inhibitor A20 is a ubiquitin-modifying enzyme that might be critical in preventing human inflammatory diseases. Here, we report that A20-deficient macrophages, unlike normal cells, exhibit spontaneous NLRP3 inflammasome activity to LPS alone. The kinase RIPK3, but not the adaptor MyD88, is required for this response. In normal cells, A20 constitutively associates with caspase-1 and pro-IL-1β, and NLRP3 activation further promotes A20 recruitment to the inflammasome. Pro-IL-1β also co-immunoprecipitates with RIPK1, RIPK3, caspase-1, and caspase-8 in a complex that is modified with K63-linked and unanchored polyubiquitin. In A20-deficient macrophages, this pro-IL-1β-associated ubiquitination is markedly increased in a RIPK3-dependent manner. Mass spectrometric and mutational analyses reveal that K133 of pro-IL-1β is a physiological ubiquitination site that supports processing. Our study reveals a mechanism by which A20 prevents inflammatory diseases.

PMID:
25607459
PMCID:
PMC4302274
DOI:
10.1016/j.immuni.2014.12.031
[Indexed for MEDLINE]
Free PMC Article

Publication types, MeSH terms, Substances, Grant support

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center